Views & Analysis Measuring and celebrating making a difference Aurora’s Siân Hurst and Chris Bath explain how using data-driven insights to build comms programmes can lead to more impactful outcomes for clients and patients
News Avalyn seeks $300m from its IPO Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.